Another phase I/II trial (ClinicalTrials.gov identifier NCT02521051) found that the treatment of alectinib plus bevacizumab was well tolerated without unanticipated toxicities or dose-limiting toxicities in patients with advanced ALK-rearranged NSCLC (24). The gene discussed is ALK; the disease is non-small cell lung carcinoma.